|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SCUBE3 |
Gene summary for SCUBE3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SCUBE3 | Gene ID | 222663 |
| Gene name | signal peptide, CUB domain and EGF like domain containing 3 | |
| Gene Alias | CEGF3 | |
| Cytomap | 6p21.31 | |
| Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q8IX30 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 222663 | SCUBE3 | male-WTA | Human | Thyroid | PTC | 3.10e-11 | 7.63e-02 | 0.1037 |
| 222663 | SCUBE3 | PTC06 | Human | Thyroid | PTC | 1.37e-17 | 3.90e-01 | 0.2057 |
| 222663 | SCUBE3 | PTC07 | Human | Thyroid | PTC | 8.31e-05 | 1.31e-01 | 0.2044 |
| 222663 | SCUBE3 | ATC13 | Human | Thyroid | ATC | 3.24e-04 | 1.70e-02 | 0.34 |
| 222663 | SCUBE3 | ATC5 | Human | Thyroid | ATC | 1.02e-03 | 3.64e-02 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SCUBE3 | SNV | Missense_Mutation | novel | c.310N>A | p.Ala104Thr | p.A104T | Q8IX30 | protein_coding | tolerated(0.18) | probably_damaging(0.995) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SCUBE3 | SNV | Missense_Mutation | rs754552974 | c.1718N>A | p.Arg573Gln | p.R573Q | Q8IX30 | protein_coding | tolerated(0.11) | probably_damaging(0.978) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SCUBE3 | SNV | Missense_Mutation | rs368342758 | c.2533N>A | p.Val845Met | p.V845M | Q8IX30 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SCUBE3 | SNV | Missense_Mutation | novel | c.107G>A | p.Gly36Glu | p.G36E | Q8IX30 | protein_coding | deleterious(0.01) | possibly_damaging(0.812) | TCGA-BG-A222-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SCUBE3 | SNV | Missense_Mutation | novel | c.1783N>T | p.Arg595Cys | p.R595C | Q8IX30 | protein_coding | deleterious(0) | possibly_damaging(0.869) | TCGA-BG-A2L7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR |
| SCUBE3 | SNV | Missense_Mutation | c.1678N>A | p.Ala560Thr | p.A560T | Q8IX30 | protein_coding | tolerated(0.74) | benign(0.202) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| SCUBE3 | SNV | Missense_Mutation | c.2523N>T | p.Lys841Asn | p.K841N | Q8IX30 | protein_coding | deleterious(0.03) | possibly_damaging(0.864) | TCGA-BS-A0UV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| SCUBE3 | SNV | Missense_Mutation | novel | c.2297N>T | p.Ala766Val | p.A766V | Q8IX30 | protein_coding | deleterious(0.02) | benign(0.378) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| SCUBE3 | SNV | Missense_Mutation | c.1385N>G | p.Asn462Ser | p.N462S | Q8IX30 | protein_coding | tolerated(0.86) | benign(0) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SCUBE3 | SNV | Missense_Mutation | novel | c.2906N>G | p.His969Arg | p.H969R | Q8IX30 | protein_coding | deleterious(0) | benign(0.15) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |